Hinge Health: Earnings Were Strong, But The Multiple Already Reflects It

Hinge Health's Q2 quarter was undeniably good. Revenue hit $212.8 million, up 53% year-over-year, beating consensus of $201.5 million. Non-GAAP operating margin (profit after operating costs, excluding stock-based compensation and other one-time items) expanded to 29% from 19% a year ago. Free cash flow tripled to $99.6 million from $32.6 million. Management raised full-year guidance and announced a $105 million acquisition to push into gastrointestinal care.

The quarter is the kind of print that justifies a "powerful earnings" headline. The question for the investor is whether the stock's move has already done the work ahead of the business. That is the rating question.

The earnings beat is real, but so is the valuation that has built around it. Hinge Health closed the session at $80.79 - up 74% year-to-date and up roughly 108% over the past four months from a 52-week low of $30.08. The stock has nearly reached its 52-week high of $91.50. At a $6.25 billion market cap and 9.2 times enterprise value to sales, this is no longer a deeply discounted digital health name. It is a stock priced for sustained execution.

That is not to say the business hasn't earned its rally. The operating metrics behind the quarter are the strongest in the company's history as a public company.

Revenue growth has accelerated rather than decelerated. Q1 was 47% year-over-year; Q2 was 53%. The company now has 2,929 clients, up 24% from a year ago, and trailing-twelve-month billings of $861.8 million, up 52%. Gross margin hit 87% on a non-GAAP basis, up from 83% a year ago, and was 86% on a GAAP basis (including stock-based compensation), up from 70%. That GAAP gross margin expansion is significant - it means the company is scaling efficiency even before you add back accounting adjustments.

Free cash flow is the part of the quarter that matters most. Twelve-month trailing free cash flow of $202.8 million, up 144% year-over-year, represents a 31% free cash flow margin. For context, that is an unusually high conversion rate for a company still growing revenue in the low-50s percent range. Most growth-stage operators sacrifice cash flow for scale. Hinge Health is doing both simultaneously, which is what has changed the risk equation.

On the earnings side, non-GAAP diluted EPS came in at $0.59 versus a consensus estimate of $0.615 - a slight miss. That is not a disaster, but it signals that operating leverage is not yet perfectly aligned with top-line acceleration. Stock buybacks are propping up per-share arithmetic: the company has repurchased $196.5 million of its $496.5 million authorized program, shrinking the share count by 2.5% from Q4 to Q1. Without those repurchases, EPS growth would be thinner.

The forward guidance tells the story of where the company is headed next. For Q3, management expects revenue of $223–$225 million (45% year-over-year growth at the midpoint) and non-GAAP operating income of $61–$63 million (a 28% margin). For the full year, raised guidance puts revenue at $856–$860 million (46% growth) and non-GAAP operating income at $236–$244 million (28% margin). The market expects a significant step-up in EPS, which is a high bar given Q2's $0.59. That implies a substantial step-up in profitability that the market is now asking for.

The Cylinder Health acquisition is the narrative layer on top of the operating numbers. Hinge Health is paying $105 million in cash for a virtual-first digestive care company with nearly 100 clients, two million covered lives, and partnerships with two of the three largest PBMs (pharmacy benefit managers, the intermediaries that negotiate drug prices for health plans). The integrated GI Care Program is expected to launch in 2027. That is a meaningful addressable market - GI conditions affect roughly one in four U.S. adults and drive $135 billion in annual medical spend - but it is also a meaningful distance away. The revenue contribution from this deal does not begin until next year, and integration risk is real.

Here is where the rating call comes down to risk versus reward at the current price.

The bullish case is straightforward: the company has demonstrated that its AI-powered care model scales with margin expansion and strong cash flow. Client growth is accelerating, gross margins are near 87%, and free cash flow is the fastest-growing metric on the income statement. If Hinge Health hits the top end of its full-year guidance at $860 million in revenue with a 28% non-GAAP operating margin, that implies roughly $240 million in adjusted operating profit, or roughly $64–68 million per quarter in the second half. At that rate, the stock would be about 26 times forward non-GAAP operating income. That is a fair multiple for a 45%+ growth company with 30%+ FCF margins.

The problem is the market has already priced that outcome in. The stock is trading at its highs, not its lows. The consensus analyst price target of $81.18 is essentially at today's price. The range spans from $45 (Evercore, April) to $125 (KeyBanc, July). At $80.79, the market is not offering a margin of safety. It is offering fair value for a company that needs to execute on aggressive Q3 EPS guidance, close a new acquisition, integrate a GI program by 2027, and maintain 45%+ revenue growth through a $860 million base.

If any one of those elements stumbles - revenue growth slows toward the low-40s, Q3 EPS comes in closer to $0.70 than the consensus estimate, or the Cylinder integration proves messy - the multiple gets tested. A growth stock at the top of its 52-week range needs momentum to stay there.

What would change this call.

A pullback toward the $65–$70 zone - roughly 15–20% below current levels - would present a more compelling entry. At that price, the 9.2x EV/sales multiple compresses toward 7.5x, and the risk/reward resets in favor of the buyer. A miss on Q3 revenue or a material softening in full-year guidance would be a negative catalyst that forces that valuation reset.

Conversely, a Q3 that beats on both revenue and EPS while guiding 2027 growth above 40% could validate the current multiple and push the stock toward its 52-week high. But that requires flawless execution, and the Q3 consensus EPS bar is not a low bar - it is a steep one relative to Q2's $0.59.

Rating: Hold. The earnings are strong, the cash flow is strong, and the client momentum is real. But the valuation bridge is built. The stock has moved from a beaten-down digital health name to a fairly valued growth story, and the next revenue catalyst from the Cylinder acquisition is 2027, not 2026. Wait for a better entry or a confirmed inflection in Q3 before adding exposure.